Abbisko Cayman Limited (2256.HK)

3.300 -0.100 (-2.94%) At close: 04:08PM HKT

Abbisko Cayman Limited

Building 3
No. 898 Halei Road Zhangjiang Hi-Tech Park Pudong New Area
Shanghai
China
86 21 6891 2098
https://www.abbisko.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 258

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yao-Chang Xu	Founder, Chairman of the Board & CEO	11.41M	N/A	1957
Dr. Hongping Yu	Co-Founder, Joint Company Secretary, Senior VP-Chemistry, Chief Scientific Officer & Exe. Director	3.68M	N/A	1968
Dr. Zhui Chen	Co-Founder, Senior VP of Biology, Chief Scientific Officer & Executive Director	7.1M	N/A	1974
Dr. Zidong Zhang	Chief Financial Officer	N/A	N/A	1981
Mr. Yongyi Li	General Counsel	N/A	N/A	1976
Ms. Jia Feng	Head of Human Resource	N/A	N/A	N/A
Dr. Zhen Zhang	VP of CMC & Head of Chemistry, Manufacturing and Controls	N/A	N/A	1973
Dr. Jing Ji	Chief Medical Officer	N/A	N/A	1970
Ms. Yin Wah Chan FCCA, FCIS, FCS, HKICS	Joint Company Secretary	N/A	N/A	1975

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Corporate governance

Abbisko Cayman Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.